• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

    2/14/23 11:25:54 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care
    Get the next $QNRX alert in real time by email
    SC 13G/A 1 tm235037d26_sc13ga.htm SC 13G/A

     

    CUSIP No: 74907L201

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Quoin Pharmaceuticals Ltd.

    (Name of Issuer)

     

    Ordinary Shares, no par value

    (Title of Class of Securities)

     

    74907L201
    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨  Rule 13d-1(b)
      x  Rule 13d-1(c)
      ¨  Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 74907L201

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    1,272,737,541
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    1,272,737,541

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        1,272,737,541
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 74907L201

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    1,272,737,541
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    1,272,737,541

     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        1,272,737,541
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        4.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 74907L201

     

    Item 1.

     

    (a)Name of Issuer

     

    Quoin Pharmaceuticals Ltd. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    42127 Pleasant Forest Ct., Ashburn, VA 20148

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the ordinary shares of the Company, no par value (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Ordinary shares, no par value

     

    Item 2(e) CUSIP Number

     

    74907L201. The CUSIP Number applies to the American Depositary Shares, each of which represents five thousand (5,000) Shares.

     

     

     

     

    CUSIP No: 74907L201

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares, represented by American Depositary Shares, issuable upon the exercise of warrants to purchase American Depositary Shares (the “Warrants”). Each American Depositary Share represents five thousand (5,000) Shares. The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Prospectus Supplement No. 6 (to Prospectus dated August 5, 2022, Registration No. 333-266476), filed on November 10, 2022, indicates there were 24,233,024,799 Shares outstanding as of September 30, 2022.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 74907L201

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 74907L201

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2023

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.
    pursuant to a Limited Power of Attorney, a copy of which was previously filed
      By: /s/ Brian Sopinsky
      Name: Brian Sopinsky
      Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 74907L201

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

    *Previously filed 

     

     

     

    Get the next $QNRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QNRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 13, 2025. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products t

      5/6/25 8:00:00 AM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

      ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company's ordinary shares was at or

      4/30/25 7:30:00 AM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton" Series, as part of its ongoing NETHERTON NOW awareness campaign

      Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announced the release of the second episode in its "Living with Netherton" video series, part of the company's broader NETHERTON NOW awareness campaign. This

      4/10/25 7:30:00 AM ET
      $QNRX
      Medical/Dental Instruments
      Health Care

    $QNRX
    Financials

    Live finance-specific insights

    See more
    • Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

      Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024. Quoin CEO Dr. Michael Myers said, "The third quarter has been marked by notable achievements, including expanding the c

      11/7/24 8:00:00 AM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

      Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites Announced Plans to Initiate Clinical Study in Peeling Skin Syndrome Continues to Evaluate M&A Opportunities in Rare and Orphan Diseases ASHBURN, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and six months ended June 30,

      8/8/24 8:30:00 AM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

      ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024. The Company will host a conference call and webcast at 8:30am ET on Thursday, March 14, 2024.   The call will include a discussion of fourth quarter and 2023 financial results and a corporate update.   The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international). The live and archived webcast of the

      3/7/24 4:05:00 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care

    $QNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $QNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $QNRX
    SEC Filings

    See more
    • Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

      4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

      12/27/24 5:17:23 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

      4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

      12/27/24 5:16:51 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

      4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

      12/27/24 5:15:10 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

      SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

      11/14/24 7:23:29 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

      2/13/24 8:11:42 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

      2/14/23 2:40:46 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Other Events

      8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

      4/30/25 5:09:32 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders

      8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

      4/4/25 4:05:31 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders

      8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)

      4/4/25 8:30:21 AM ET
      $QNRX
      Medical/Dental Instruments
      Health Care

    $QNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

      4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

      12/27/24 5:17:23 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Myers Michael bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,176% to 602,808 units (SEC Form 4)

      4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

      12/27/24 5:16:51 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care
    • Director Culverwell Anthony James bought $45,000 worth of Ordinary Shares (100,000 units at $0.45), increasing direct ownership by 31,546% to 100,317 units (SEC Form 4)

      4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

      12/27/24 5:15:10 PM ET
      $QNRX
      Medical/Dental Instruments
      Health Care